Neuralstem, Inc. (NASDAQ:CUR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 18, 2017, Neuralstem, Inc. (the “Company”) was informed by Tianjin Pharmaceuticals Group International Holdings Co., LTD (“Tianjin”) that Xi Chen, Ph.D. is being appointed to replace Zhang Zhuo as the director appointee of the Company’s Series A 4.5% Convertible Preferred Stock (“Series A Stock”). Tianjin is the sole shareholder of the Company’s Series A Stock. Dr. Chen will serve as a Class III director until the Company’s 2020 annual shareholder meeting or until such time as he resigns or is removed.
There are no family relationships among Dr. Chen and any of our executive officers or directors.
As compensation for his service on the board of directors, Dr. Chen will participate in the Company’s non-executive board compensation policy as described in the Company’s Current Report on Form 8-K filed on June 27, 2017.
A copy of the press release announcing Dr. Chen’s appointment is attached to this report as Exhibit 99.01.
Item 9.01. Financial Statements and Exhibits.
| Exhibit No. | Description |
| 99.01 | Press Release Dated December 20, 2017 |
Neuralstem, Inc. ExhibitEX-99.01 2 exh_9901.htm PRESS RELEASE EdgarFilingExhibit 99.01New Member appointed to the Board of Directors of Neuralstem GERMANTOWN,…To view the full exhibit click here
About Neuralstem, Inc. (NASDAQ:CUR)
Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company’s technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company’s NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.